RECRUITING

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Conditions

Hematopoietic and Lymphatic System Neoplasm Lymphoma Multiple Myeloma Respiratory Syncytial Virus Infection

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.

Official Title

An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies

Quick Facts

Study Start:2025-10-15

Study Completion:2027-11-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06817889

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Aged ≥ 18 years * Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved) * RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \[PCR\] or respiratory viral panel \[RVP\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing) * Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies) * Have one of the following underlying diseases and/or received one of the following treatments relative to RSV diagnosis date: * Received allogeneic hematopoietic cell transplant (HCT) with any conditioning regimen within 1 year * Received autologous HCT with any conditioning regimen within 3 months * Received Chimeric antigen receptor T cell therapy (CARTx) within 3 months * Have multiple myeloma (MM) and received bispecific antibody therapy (bsAb) within 3 months * Have lymphoma and received bsAb within 3 months * Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-12) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis: * 1 point: * Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx * Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). * 2 points: * Age ≥ 40 years * 3 points: * Absolute neutrophil count (ANC) \< 500 cells/μL within the prior 7 days * Absolute lymphocyte count (ALC) \< 200 cells/µL within the prior 7 days * Oxygen saturation (SpO2) 92% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \[O2\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 92%) at screening * Willingness to take study drug and complete necessary study procedures * Participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described	* Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days, and/or expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening * Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode * Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \< 4 months or \< 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening * Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen * Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines * Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal within 7 days prior to screening * New lower respiratory tract radiographic abnormalities after RSV-associated symptom onset that are suspected to be due to RSV * Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery) * A life expectancy of three months or less, as determined by the investigator * Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening * Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \< 92% at rest \< 24 hours prior to study drug administration * Previous infection and/or hospitalization for RSV, or previous infection with, treatment for, or hospitalization for another respiratory viral infection within 28 days prior to screening * Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \[including SARS-CoV-2\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required) * Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator * Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator * Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator * Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study * Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients

Inclusion Criteria

Exclusion Criteria

* Aged ≥ 18 years
* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)
* RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \[PCR\] or respiratory viral panel \[RVP\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)
* Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)
* Have one of the following underlying diseases and/or received one of the following treatments relative to RSV diagnosis date:
* Received allogeneic hematopoietic cell transplant (HCT) with any conditioning regimen within 1 year
* Received autologous HCT with any conditioning regimen within 3 months
* Received Chimeric antigen receptor T cell therapy (CARTx) within 3 months
* Have multiple myeloma (MM) and received bispecific antibody therapy (bsAb) within 3 months
* Have lymphoma and received bsAb within 3 months
* Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-12) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis:
* 1 point:
* Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx
* Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
* 2 points:
* Age ≥ 40 years
* 3 points:
* Absolute neutrophil count (ANC) \< 500 cells/μL within the prior 7 days
* Absolute lymphocyte count (ALC) \< 200 cells/µL within the prior 7 days
* Oxygen saturation (SpO2) 92% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \[O2\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 92%) at screening
* Willingness to take study drug and complete necessary study procedures
* Participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described

* Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days, and/or expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening
* Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode
* Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \< 4 months or \< 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening
* Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen
* Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines
* Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal within 7 days prior to screening
* New lower respiratory tract radiographic abnormalities after RSV-associated symptom onset that are suspected to be due to RSV
* Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery)
* A life expectancy of three months or less, as determined by the investigator
* Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening
* Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \< 92% at rest \< 24 hours prior to study drug administration
* Previous infection and/or hospitalization for RSV, or previous infection with, treatment for, or hospitalization for another respiratory viral infection within 28 days prior to screening
* Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \[including SARS-CoV-2\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required)
* Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator
* Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator
* Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator
* Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study
* Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients

Contacts and Locations

Study Contact

Joshua Hill, MD

CONTACT

206-667-6504

Jahill3@fredhutch.org

Principal Investigator

Joshua Hill, MD

PRINCIPAL_INVESTIGATOR

Fred Hutch/University of Washington Cancer Consortium

Study Locations (Sites)

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

United States

MD Anderson Cancer Center

Houston, Texas, 77030

United States

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109

United States

Collaborators and Investigators

Sponsor: Fred Hutchinson Cancer Center

Joshua Hill, MD, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-10-15

Study Completion Date2027-11-30

Study Record Updates

Study Start Date2025-10-15

Study Completion Date2027-11-30

Terms related to this study

Additional Relevant MeSH Terms

Hematopoietic and Lymphatic System Neoplasm
Lymphoma
Multiple Myeloma
Respiratory Syncytial Virus Infection